Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 2
1977 4
1978 4
1979 6
1980 7
1981 7
1982 5
1983 10
1984 8
1985 7
1986 7
1987 4
1988 2
1989 5
1990 7
1991 4
1992 5
1993 3
1994 8
1995 8
1996 4
1997 2
1998 6
1999 5
2000 7
2001 7
2002 6
2003 2
2004 6
2005 12
2006 7
2007 12
2008 10
2009 9
2010 9
2011 12
2012 8
2013 12
2014 6
2015 7
2016 8
2017 12
2018 6
2019 4
2020 8
2021 6
Text availability
Article attribute
Article type
Publication date

Search Results

281 results
Results by year
Filters applied: . Clear all
Page 1
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA. Brock PR, et al. Among authors: neuwelt ea. N Engl J Med. 2018 Jun 21;378(25):2376-2385. doi: 10.1056/NEJMoa1801109. N Engl J Med. 2018. PMID: 29924955 Free PMC article. Clinical Trial.
The Translational Significance of the Neurovascular Unit.
McConnell HL, Kersch CN, Woltjer RL, Neuwelt EA. McConnell HL, et al. Among authors: neuwelt ea. J Biol Chem. 2017 Jan 20;292(3):762-770. doi: 10.1074/jbc.R116.760215. Epub 2016 Dec 5. J Biol Chem. 2017. PMID: 27920202 Free PMC article. Review.
Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
Freyer DR, Chen L, Krailo MD, Knight K, Villaluna D, Bliss B, Pollock BH, Ramdas J, Lange B, Van Hoff D, VanSoelen ML, Wiernikowski J, Neuwelt EA, Sung L. Freyer DR, et al. Among authors: neuwelt ea. Lancet Oncol. 2017 Jan;18(1):63-74. doi: 10.1016/S1470-2045(16)30625-8. Epub 2016 Dec 1. Lancet Oncol. 2017. PMID: 27914822 Free PMC article. Clinical Trial.
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.
Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O'Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F; International Primary CNS Lymphoma Collaborative Group. Abrey LE, et al. Among authors: neuwelt ea. J Clin Oncol. 2005 Aug 1;23(22):5034-43. doi: 10.1200/JCO.2005.13.524. Epub 2005 Jun 13. J Clin Oncol. 2005. PMID: 15955902
Sodium Thiosulfate and Cisplatin-Induced Hearing Loss.
Brock PR, Maibach R, Neuwelt EA. Brock PR, et al. Among authors: neuwelt ea. N Engl J Med. 2018 Sep 20;379(12):1181. doi: 10.1056/NEJMc1809501. N Engl J Med. 2018. PMID: 30231227 No abstract available.
Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.
Barajas RF, Hamilton BE, Schwartz D, McConnell HL, Pettersson DR, Horvath A, Szidonya L, Varallyay CG, Firkins J, Jaboin JJ, Kubicky CD, Raslan AM, Dogan A, Cetas JS, Ciporen J, Han SJ, Ambady P, Muldoon LL, Woltjer R, Rooney WD, Neuwelt EA. Barajas RF, et al. Among authors: neuwelt ea. Neuro Oncol. 2019 Mar 18;21(4):517-526. doi: 10.1093/neuonc/noy160. Neuro Oncol. 2019. PMID: 30277536 Free PMC article.
Neurovascular Unit: Basic and Clinical Imaging with Emphasis on Advantages of Ferumoxytol.
Netto JP, Iliff J, Stanimirovic D, Krohn KA, Hamilton B, Varallyay C, Gahramanov S, Daldrup-Link H, d'Esterre C, Zlokovic B, Sair H, Lee Y, Taheri S, Jain R, Panigrahy A, Reich DS, Drewes LR, Castillo M, Neuwelt EA. Netto JP, et al. Among authors: neuwelt ea. Neurosurgery. 2018 Jun 1;82(6):770-780. doi: 10.1093/neuros/nyx357. Neurosurgery. 2018. PMID: 28973554 Free PMC article. Review.
281 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page